Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

Camelinvesting Sep. 7 at 7:33 PM

$NCNA its in the “ buy before regret zone” imo Watching

0 · Reply

Spc_baller Sep. 7 at 6:39 PM

$NCNA when this pops it’s gone

0 · Reply

GuineaPigForever Sep. 7 at 1:13 PM

$NCNA Add to below... very low float. Then I apply patience and average down and accumulate if I am early.

0 · Reply

GuineaPigForever Sep. 7 at 12:34 PM

$NCNA my criteria when looking for one of these types of stocks (nfa). Recent reverse split (turning compliant), recent dilution (dropped hard for it), cash runway into the future, good posibility of positive news, low volume (short interest does not matter as we don't know where it really stands day to day), lots of 1 and 10 share trades (this is algos pinging for liquidity) and has been beaten down to hell over a short period of time.

0 · Reply

Baseball89 Sep. 6 at 11:55 PM

$NCNA Just remember......this is going to 5k-6k. This deal is and should almost be finalized imo. I know what I hold. It's time to make this stock go Boom Boom!! I love this stock.

1 · Reply

Bahrouh Sep. 6 at 12:23 AM

NuCana ($NCNA) with two key updates: 1️⃣ The company is back in compliance with Nasdaq rules, removing the risk of delisting. 2️⃣ NuCana will present new preclinical data on NUC-7738 at ESMO 2025 (Oct 13 abstract, Oct 19 poster). The data highlights potential synergy with PD-1 inhibitors (e.g., Keytruda) in renal cell cancer. These developments give NuCana breathing room operationally and a potential scientific catalyst heading into Q4.

1 · Reply

Powell65311 Sep. 5 at 11:15 PM

$HCTI $SPY $OPEN $NCNA 👀👀👀👀 Good Call

0 · Reply

Brachina Sep. 5 at 8:11 PM

$NCNA another fucking day

0 · Reply

Kneezy27 Sep. 5 at 8:04 PM

$HCTI Closing above the high of the day. Looking like next week will be a runner! $SPY $OPEN $NCNA

1 · Reply

minybombayprincess Sep. 5 at 7:45 PM

$HCTI Glad to see its still heading in the right direction. Still want to add more from the Pharma sector to my portfolio. Probably a Dumb Ass idea. Been looking at NVO & VKTX but still look like they have aways to go before hitting the floor. I've caught enough falling knives before. Ran out of Band-Aids. Hopefully my $HCTI buy will help heal some wounds from $NCNA. Will be babysitting that one for a while, like maybe forever lol.

0 · Reply

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 4 days ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 17 days ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 4:05 PM EDT - 5 weeks ago

NuCana Announces ADS Ratio Change

Jul 21, 2025, 8:05 AM EDT - 6 weeks ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 2 months ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 3 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 6 months ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 7 months ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Nov 25, 2024, 7:00 AM EST - 10 months ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 10 months ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 1 year ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 1 year ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Jan 3, 2024, 2:39 AM EST - 1 year ago

NuCana: Potential Turnaround In 2024 But Risky

Nov 16, 2023, 4:01 PM EST - 1 year ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 1 year ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 1 year ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 2 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 2 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 2 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 2 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 2 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 8, 2023, 4:30 AM EST - 2 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 6, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 22, 2022, 3:40 PM EDT - 3 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Aug 31, 2022, 8:00 AM EDT - 3 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 17, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Jul 13, 2022, 6:00 AM EDT - 3 years ago

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 11, 2022, 1:52 PM EDT - 3 years ago

Why NuCana Shares Are Rising Today?

Camelinvesting Sep. 7 at 7:33 PM

$NCNA its in the “ buy before regret zone” imo Watching

0 · Reply

Spc_baller Sep. 7 at 6:39 PM

$NCNA when this pops it’s gone

0 · Reply

GuineaPigForever Sep. 7 at 1:13 PM

$NCNA Add to below... very low float. Then I apply patience and average down and accumulate if I am early.

0 · Reply

GuineaPigForever Sep. 7 at 12:34 PM

0 · Reply

Baseball89 Sep. 6 at 11:55 PM

$NCNA Just remember......this is going to 5k-6k. This deal is and should almost be finalized imo. I know what I hold. It's time to make this stock go Boom Boom!! I love this stock.

1 · Reply

Bahrouh Sep. 6 at 12:23 AM

1 · Reply

Powell65311 Sep. 5 at 11:15 PM

$HCTI $SPY $OPEN $NCNA 👀👀👀👀 Good Call

0 · Reply

Brachina Sep. 5 at 8:11 PM

$NCNA another fucking day

0 · Reply

Kneezy27 Sep. 5 at 8:04 PM

$HCTI Closing above the high of the day. Looking like next week will be a runner! $SPY $OPEN $NCNA

1 · Reply